TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15889658

Group type: EXPERIMENTAL
Intervention: Fuji Plus with AdheSE
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Fuji Plus with Xeno III
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Fuji Plus with Clearfil SEBond
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Fuji Plus with Unifil Bond
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Fuji Plus with experimental self-etching bonding system (Xeno III and SE Bond)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Fuji Plus with conditioner (10% ferric chloride, 2% citric acid solution)
Number of subjects: 105

Group type: COMPARATOR
Intervention: SuperBond
Number of subjects: 105
Study: 11958301

Group type: EXPERIMENTAL
Intervention: Zero-balance ultrafiltration (ZBUF)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no ultrafiltration)
Number of subjects: 30
Study: 9972143

Group type: EXPERIMENTAL
Intervention: Low-dose doxycycline (LDD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 7644243

Group type: EXPERIMENTAL
Intervention: NE-21610 (0.3, 3.0, 10 micrograms)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: NE-21610 (100 micrograms, s.c.)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Vehicle (s.c. control)
Number of subjects: 31
Study: 2651472

Group type: EXPERIMENTAL
Intervention: RU 486 (25 mg twice daily for 4 days) + PGE2 (1 mg once or twice)
Number of subjects: 42

Group type: COMPARATOR
Intervention: RU 486 (25 mg twice daily for 4 days) + Placebo
Number of subjects: 42
Study: 342679

Group type: EXPERIMENTAL
Intervention: Enzyme tablets (mutanase and protease)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 40
Study: 31568024

Group type: EXPERIMENTAL
Intervention: 40% rAOP
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 40% eAOP
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 40% to 80% rAOP
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: eAOP
Number of subjects: 23
Study: 30762663

Group type: EXPERIMENTAL
Intervention: Brief Cognitive Behavioral Intervention (CBI)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control intervention (information about pain)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Interaction between tDCS and CBI
Number of subjects: 72
Study: 27606825

Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sugar placebo
Number of subjects: 0
Study: 25767256

Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted atazanavir
Number of subjects: 1797

Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted darunavir
Number of subjects: 1797

Group type: COMPARATOR
Intervention: Raltegravir
Number of subjects: 1797
Study: 23503548

Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Sodium Valproate (VPA)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 53
Study: 21626572

Group type: EXPERIMENTAL
Intervention: Cognitive processing therapy (CPT) immediately
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cognitive processing therapy (CPT) after 10 weeks
Number of subjects: 60
Study: 20095196

Group type: EXPERIMENTAL
Intervention: Diamond burs
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Self‐glaze
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Overglaze
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Reglaze
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pearl Surface polishing system
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Diamond Twist SCL
Number of subjects: 60
Study: 16691031

Group type: EXPERIMENTAL
Intervention: Immunotherapy (n = 41)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo (n = 41)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 15310546

Group type: EXPERIMENTAL
Intervention: Cyst evacuation plus PEI (50 to 70% of cystic fluid extracted)
Number of subjects: 281

Group type: COMPARATOR
Intervention: Simple cyst evacuation
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Cyst evacuation plus PEI
Number of subjects: 281
Study: 11781766

Group type: EXPERIMENTAL
Intervention: Mixed treatment incorporating both group and individualized treatment
Number of subjects: 31

Group type: COMPARATOR
Intervention: Group treatment only
Number of subjects: 31
Study: 9403648

Group type: EXPERIMENTAL
Intervention: Glutamine-supplemented premature formula
Number of subjects: 68

Group type: COMPARATOR
Intervention: Premature formula alone (Control)
Number of subjects: 68
Study: 8509313

Group type: EXPERIMENTAL
Intervention: Aspirin (320 mg, three tablets every six hours)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (identical schedule as aspirin)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Post-test condition (one week after testing in the first two conditions)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Aspirin and placebo (double-blind administration)
Number of subjects: 8
Study: 3542984

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 99

Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 99
Study: 30045179

Group type: EXPERIMENTAL
Intervention: Chitosan nerve tube in primary nerve repair
Number of subjects: 74

Group type: COMPARATOR
Intervention: Microsurgical nerve repair alone (Control)
Number of subjects: 74
Study: 27119579

Group type: EXPERIMENTAL
Intervention: SAR164653 (20 to 800 mg single oral doses, repeat doses up to 800 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SAR164653 (single dosing)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SAR164653 (multiple dosing)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SAR164653
Number of subjects: 0
Study: 24476560

Group type: EXPERIMENTAL
Intervention: Primary School Free Breakfast Initiative
Number of subjects: 4500

Group type: COMPARATOR
Intervention: Control (wait-list)
Number of subjects: 4500
Study: 23147343

Group type: EXPERIMENTAL
Intervention: Piezosurgery
Number of subjects: 29

Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 29
Study: 20465172

Group type: EXPERIMENTAL
Intervention: Facial width-to-height ratio
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emotionally neutral faces varying in perceived threat
Number of subjects: 0
Study: 18538928

Group type: EXPERIMENTAL
Intervention: Verbal suggestion alone (Group 1)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Conditioning procedure (Group 2)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (Group 3)
Number of subjects: 44
Study: 16613888

Group type: EXPERIMENTAL
Intervention: Laser-assisted hatching (LAH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no assisted hatching)
Number of subjects: 0
Study: 14622313

Group type: EXPERIMENTAL
Intervention: High impedance ventricular leads
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard impedance ventricular leads
Number of subjects: 40
Study: 11085757

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention including provision of information, coping skills training, and parent coaching
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 40
Study: 9002829

Group type: EXPERIMENTAL
Intervention: Test implants (subcrestal placement, polished surface sunk by 1 mm)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Test implants (subcrestal placement)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control implants (placed at alveolar crest)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Test implants
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Modified gingival index at 4 months (test implants)
Number of subjects: 11
Study: 1335003

Group type: EXPERIMENTAL
Intervention: Untreated essential hypertensives
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treated essential hypertensives (propranolol therapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: First-degree blood relatives of essential hypertensives
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normotensive control subjects
Number of subjects: 0
Study: 6704507

Group type: EXPERIMENTAL
Intervention: Chlorothiazide administered as a solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chlorothiazide administered as a tablet
Number of subjects: 0
Study: 31145817

Group type: EXPERIMENTAL
Intervention: Tissue-hybrid simulator (REAL)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Synthetic simulated umbilical cord task trainer (ART)
Number of subjects: 27
Study: 28892645

Group type: EXPERIMENTAL
Intervention: P11-4 + fluoride varnish
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluoride varnish alone
Number of subjects: 0
Study: 27291387

Group type: EXPERIMENTAL
Intervention: Combined treatment with fractional CO2 laser, targeted UVB phototherapy, and topical 0.05% clobetasol propionate cream
Number of subjects: 14

Group type: COMPARATOR
Intervention: Targeted UVB phototherapy and topical 0.05% clobetasol propionate cream
Number of subjects: 14
Study: 24479388

Group type: EXPERIMENTAL
Intervention: Protein-supplemented food service concept
Number of subjects: 84

Group type: COMPARATOR
Intervention: Standard hospital menu
Number of subjects: 84
Study: 22704766

Group type: EXPERIMENTAL
Intervention: Double-balloon catheter
Number of subjects: 210

Group type: COMPARATOR
Intervention: PGE2 vaginal insert
Number of subjects: 210
Study: 20413054

Group type: EXPERIMENTAL
Intervention: Nurse-directed intervention (six-contact, eight-week)
Number of subjects: 437

Group type: COMPARATOR
Intervention: Automated telephone symptom management intervention
Number of subjects: 437
Study: 17664919

Group type: EXPERIMENTAL
Intervention: 27G x 35 mm standard needle with internal caliber of 0.215 mm
Number of subjects: 266

Group type: COMPARATOR
Intervention: 27G x 35 mm XL Monoprotect needle with internal caliber of 0.265 mm
Number of subjects: 266
Study: 16269974

Group type: EXPERIMENTAL
Intervention: Valsartan (160 mg/day)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Atenolol (100 mg/day)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 132

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 132
Study: 11983186

Group type: EXPERIMENTAL
Intervention: Fluoxetine (dose stratified from 1.25 mg to 40 mg per day)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Fluoxetine (dose response)
Number of subjects: 51
Study: 10071830

Group type: EXPERIMENTAL
Intervention: Normaten FC (generic atenolol)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Tenormin (innovator atenolol)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Normaten FC
Number of subjects: 12

Group type: COMPARATOR
Intervention: Tenormin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both products
Number of subjects: 12
Study: 7747370

Group type: EXPERIMENTAL
Intervention: IFN‐alpha and vinblastine (VBL)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Medroxyprogesterone acetate (MPA)
Number of subjects: 41
Study: 1771902

Group type: EXPERIMENTAL
Intervention: High-dose intravenous immunoglobulin (IgIV) (0.4 g/kg during 5 consecutive days, total dose of 2.0 g/kg)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Plasma exchange (PE)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: High-dose intravenous immunoglobulin (IgIV)
Number of subjects: 150
Study: 6460558

Group type: EXPERIMENTAL
Intervention: mezlocillin
Number of subjects: 89

Group type: COMPARATOR
Intervention: carbenicillin
Number of subjects: 89
Study: 31779620

Group type: EXPERIMENTAL
Intervention: Communication training for patients and their social support providers (n=423) in a randomized controlled study.
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: App supporting communication between staff, patients, and their social support providers (n=423) in a case-control study.
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: Training for staff (n=140) tested in a pre-experimental study with a pre/post-design.
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: Communication interventions including an app.
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: Implementation outcomes including pAEs, patient/treatment satisfaction, work satisfaction, safety culture, training-related outcomes.
Number of subjects: 563
Study: 29855317

Group type: EXPERIMENTAL
Intervention: Life skills building education and multiple micronutrient supplementation provided bi-monthly from preconception, twice-weekly during preconception, daily during pregnancy, and daily for 6 months post-partum.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care including non-regulated community-based health sessions and daily iron and folic acid supplementation during pregnancy.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Life skills building education and multiple micronutrient supplementation.
Number of subjects: 0
Study: 27237018

Group type: EXPERIMENTAL
Intervention: Multiple micronutrient powder (MNP) daily in complementary feeding for 2 months
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control group (CG) without MNP
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Multiple micronutrient powder (MNP)
Number of subjects: 240
Study: 24577485

Group type: EXPERIMENTAL
Intervention: High-dose edoxaban
Number of subjects: 0

Group type: COMPARATOR
Intervention: Apixaban
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dabigatran 150 mg bid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rivaroxaban
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-dose edoxaban
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dabigatran 110 mg bid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dabigatran 150 mg bid and Rivaroxaban
Number of subjects: 0
Study: 22236802

Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study: 20818821

Group type: EXPERIMENTAL
Intervention: Bismuth pectin quadruple therapy (20 mg rabeprazole bid, 1000 mg amoxicillin bid, 100 mg bismuth pectin qid, and 500 mg levofloxacin qd)
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Sequential therapy (20 mg omeprazole bid, 1000 mg amoxicillin bid for 5 d, followed by 20 mg omeprazole bid, 500 mg tinidazole bid, 500 mg clarithromycin bid for another 5 d)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Standard triple therapy (20 mg omeprazole bid, 1000 mg amoxicillin bid, 500 mg clarithromycin bid)
Number of subjects: 215
Study: 17192116

Group type: EXPERIMENTAL
Intervention: Pharmacy-based coaching programme (3 contacts with pharmacist, mean duration 13-20 minutes)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 151
Study: 15193180

Group type: EXPERIMENTAL
Intervention: vax‐SPIRAL vaccine
Number of subjects: 101832

Group type: COMPARATOR
Intervention: Heberbiovac‐HB (control vaccine)
Number of subjects: 101832
Study: 11522460

Group type: EXPERIMENTAL
Intervention: 4 mg nicotine gum
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 9753212

Group type: EXPERIMENTAL
Intervention: Azithromycin (therapeutic doses) with rifabutin 300 mg/day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Clarithromycin (therapeutic doses) with rifabutin 300 mg/day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Rifabutin 300 mg/day alone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Clarithromycin with rifabutin
Number of subjects: 30
Study: 7831625

Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Adrenaline
Number of subjects: 8
Study: 3364811

Group type: EXPERIMENTAL
Intervention: Etomidate (0.3 and 0.15 mg.kg‐1 respectively)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Thiopentone (3 and 1.5 mg.kg‐1 respectively)
Number of subjects: 80
Study: 29607631

Group type: EXPERIMENTAL
Intervention: Coronally-advanced flap along with placental membrane (group II)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Coronally-advanced flap alone (group I)
Number of subjects: 15
Study: 28699554

Group type: EXPERIMENTAL
Intervention: Temephos application in intervention sites
Number of subjects: 10491

Group type: COMPARATOR
Intervention: Control sites without intervention
Number of subjects: 10491

Group type: EXPERIMENTAL
Intervention: Intervention clusters
Number of subjects: 10491

Group type: COMPARATOR
Intervention: Control clusters
Number of subjects: 10491

Group type: EXPERIMENTAL
Intervention: Intervention sites
Number of subjects: 10491

Group type: COMPARATOR
Intervention: Control sites
Number of subjects: 10491
Study: 25488056

Group type: EXPERIMENTAL
Intervention: Saccharomyces cerevisiae (500 mg once daily for 8 weeks)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study: 23047002

Group type: EXPERIMENTAL
Intervention: ranibizumab
Number of subjects: 1105

Group type: EXPERIMENTAL
Intervention: bevacizumab
Number of subjects: 1105

Group type: COMPARATOR
Intervention: ranibizumab or bevacizumab
Number of subjects: 1105
Study: 21782352

Group type: EXPERIMENTAL
Intervention: Buprenorphine (n=15)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (n=12)
Number of subjects: 36
Study: 17943923

Group type: EXPERIMENTAL
Intervention: D-optimal design for complete data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: D-optimal design for data with dropout
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: D-optimal design points for the dropout case
Number of subjects: 0
Study: 14697066

Group type: EXPERIMENTAL
Intervention: Infant orthopedic treatment (IO)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-infant orthopedic treatment (non-IO)
Number of subjects: 20
Study: 10667615

Group type: EXPERIMENTAL
Intervention: CCK‐4 (0.5 mg/60 min)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: CCK‐4
Number of subjects: 28
Study: 8567853

Group type: EXPERIMENTAL
Intervention: Embryos from patients with PCOS
Number of subjects: 51

Group type: COMPARATOR
Intervention: Embryos from patients with tubal disease
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Surplus embryos from patients with PCOS
Number of subjects: 51

Group type: COMPARATOR
Intervention: Surplus embryos from patients with tubal disease
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Embryos from patients with anovulatory PCOS
Number of subjects: 51

Group type: COMPARATOR
Intervention: Embryos from patients with tubal disease with optimized ovulation induction regimen
Number of subjects: 51
Study: 1969198

Group type: EXPERIMENTAL
Intervention: 50 mg itraconazole daily for 3 to 6 months
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 100 mg itraconazole daily for 6 to 8 months
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 100 mg itraconazole daily for 6 months
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 50 mg itraconazole daily
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Follow-up studies
Number of subjects: 15
Study: 508557

Group type: EXPERIMENTAL
Intervention: Probenecid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no probenecid)
Number of subjects: 0
Study: 30761964

Group type: EXPERIMENTAL
Intervention: Hipcref diet (n 65)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control diet (n 63)
Number of subjects: 128
Study: 27981752

Group type: EXPERIMENTAL
Intervention: Fatigue intervention (40 contractions at 55%MVFb)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control intervention (40 contractions at 5%MVFb)
Number of subjects: 11
Study: 25715865

Group type: EXPERIMENTAL
Intervention: Intramuscular midazolam
Number of subjects: 893

Group type: COMPARATOR
Intervention: Intravenous lorazepam
Number of subjects: 893
Study: 24378762

Group type: EXPERIMENTAL
Intervention: Structured hypocaloric diet (n = 63); energy restriction (−300 to −500 kcal/d) emphasizing cardioprotective dietary changes
Number of subjects: 118

Group type: COMPARATOR
Intervention: Behavioral therapy (BT) (n = 55); goal setting, problem-solving, and stimulus control
Number of subjects: 118
Study: 23134211

Group type: EXPERIMENTAL
Intervention: linagliptin 5 mg/day
Number of subjects: 226

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 226
Study: 19670053

Group type: EXPERIMENTAL
Intervention: Telephone case management over a 12 month period
Number of subjects: 99
Study: 17561794

Group type: EXPERIMENTAL
Intervention: Simple Start DVD presentation and a 30‐min diet education course (SS Group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 30
Study: 15047649

Group type: EXPERIMENTAL
Intervention: Low-intensity laser therapy (LILT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 50
Study: 11496809

Group type: EXPERIMENTAL
Intervention: Enuresis alarm treatment
Number of subjects: 22

Group type: COMPARATOR
Intervention: Different types of enuresis alarms
Number of subjects: 22
Study: 9602874

Group type: EXPERIMENTAL
Intervention: GM-CSF (20 micrograms per wound)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Solvent control
Number of subjects: 10
Study: 7747584

Group type: EXPERIMENTAL
Intervention: Peribulbar anaesthesia (group A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subconjunctival anaesthesia (group B)
Number of subjects: 0
Study: 2557881

Group type: COMPARATOR
Intervention: Doxorubicin 60‐75 mg m‐2 intravenously once every 3 weeks
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Recombinant alpha 2 interferon (rIFN) 9‐18 x 10(6) IU m‐2 intramuscularly daily
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Recombinant alpha 2 interferon (rIFN) 25‐50 x 10(6) IU m‐2 intramuscularly three times weekly
Number of subjects: 75
Study: 31493631

Group type: EXPERIMENTAL
Intervention: Early-onset bipolar disorder (EOBD)
Number of subjects: 64854

Group type: COMPARATOR
Intervention: Adult-onset bipolar disorder (AOBD)
Number of subjects: 64854

Group type: COMPARATOR
Intervention: Control group (age-controlled comparison subjects without bipolar disorder)
Number of subjects: 64854
Study: 31046481

Group type: EXPERIMENTAL
Intervention: IL-17 inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IL-23/p19 inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Apremilast
Number of subjects: 0